Literature DB >> 22591910

Striatal dopamine D2/3 receptor binding following dopamine depletion in subjects at Ultra High Risk for psychosis.

Oswald J N Bloemen1, Mariken B de Koning, Tobias Gleich, Julia Meijer, Lieuwe de Haan, Don H Linszen, Jan Booij, Thérèse A M J van Amelsvoort.   

Abstract

Altered striatal dopaminergic neurotransmission is thought to be fundamental to schizophrenia. Increased presynaptic dopaminergic activity ([18F]-DOPA PET) may predate the onset of psychotic symptoms and correlates to clinical symptoms in subjects at Ultra High Risk (UHR) for developing psychosis. Postsynaptic dopaminergic neurotransmission has not been investigated yet in UHR patients. We hypothesized that synaptic dopamine concentration would be increased in UHR patients, and that synaptic dopamine concentration would be related to symptom severity. 14 UHR patients and 15 age and IQ matched controls completed an [123I]-IBZM SPECT scan at baseline and again after dopamine depletion with alpha-methyl-para-tyrosine (AMPT). We measured changes in radiotracer binding potential, compared these between UHR patients and controls, and correlated these to symptom severity. The UHR group as a whole did not differ significantly from controls. AMPT significantly reduced symptom severity in the UHR group (p=0.014). Higher synaptic dopamine concentration predicted larger reduction of positive symptoms following depletion in the UHR group (p=0.01). In UHR patients, positive symptoms responded to dopamine depletion, comparable to observations in schizophrenia, suggesting a similar mechanism. Higher synaptic dopamine concentration was associated with more severe positive symptoms and a greater reduction of these symptoms following depletion.
Copyright © 2012 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22591910     DOI: 10.1016/j.euroneuro.2012.04.015

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  13 in total

Review 1.  Altering the course of schizophrenia: progress and perspectives.

Authors:  Mark J Millan; Annie Andrieux; George Bartzokis; Kristin Cadenhead; Paola Dazzan; Paolo Fusar-Poli; Jürgen Gallinat; Jay Giedd; Dennis R Grayson; Markus Heinrichs; René Kahn; Marie-Odile Krebs; Marion Leboyer; David Lewis; Oscar Marin; Philippe Marin; Andreas Meyer-Lindenberg; Patrick McGorry; Philip McGuire; Michael J Owen; Paul Patterson; Akira Sawa; Michael Spedding; Peter Uhlhaas; Flora Vaccarino; Claes Wahlestedt; Daniel Weinberger
Journal:  Nat Rev Drug Discov       Date:  2016-03-04       Impact factor: 84.694

2.  Dopamine and glutamate in individuals at high risk for psychosis: a meta-analysis of in vivo imaging findings and their variability compared to controls.

Authors:  Robert A McCutcheon; Kate Merritt; Oliver D Howes
Journal:  World Psychiatry       Date:  2021-10       Impact factor: 79.683

3.  Imaging synaptic dopamine availability in individuals at clinical high-risk for psychosis: a [11C]-(+)-PHNO PET with methylphenidate challenge study.

Authors:  Ragy R Girgis; Mark Slifstein; Gary Brucato; Lawrence S Kegeles; Tiziano Colibazzi; Jeffrey A Lieberman; Anissa Abi-Dargham
Journal:  Mol Psychiatry       Date:  2020-11-05       Impact factor: 13.437

4.  Estimating the effect of endogenous dopamine on baseline [(11) C]-(+)-PHNO binding in the human brain.

Authors:  Fernando Caravaggio; Lawrence S Kegeles; Alan A Wilson; Gary Remington; Carol Borlido; David C Mamo; Ariel Graff-Guerrero
Journal:  Synapse       Date:  2016-07-11       Impact factor: 2.562

5.  Estimating endogenous dopamine levels at D2 and D3 receptors in humans using the agonist radiotracer [(11)C]-(+)-PHNO.

Authors:  Fernando Caravaggio; Shinichiro Nakajima; Carol Borlido; Gary Remington; Philip Gerretsen; Alan Wilson; Sylvain Houle; Mahesh Menon; David Mamo; Ariel Graff-Guerrero
Journal:  Neuropsychopharmacology       Date:  2014-05-30       Impact factor: 7.853

6.  A Test of the Transdiagnostic Dopamine Hypothesis of Psychosis Using Positron Emission Tomographic Imaging in Bipolar Affective Disorder and Schizophrenia.

Authors:  Sameer Jauhar; Matthew M Nour; Mattia Veronese; Maria Rogdaki; Ilaria Bonoldi; Matilda Azis; Federico Turkheimer; Philip McGuire; Allan H Young; Oliver D Howes
Journal:  JAMA Psychiatry       Date:  2017-12-01       Impact factor: 21.596

Review 7.  The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia.

Authors:  Oliver D Howes; Robert McCutcheon; Michael J Owen; Robin M Murray
Journal:  Biol Psychiatry       Date:  2016-08-06       Impact factor: 13.382

Review 8.  Glutamate and dopamine in schizophrenia: an update for the 21st century.

Authors:  Oliver Howes; Rob McCutcheon; James Stone
Journal:  J Psychopharmacol       Date:  2015-01-13       Impact factor: 4.153

Review 9.  The neurobiology and treatment of first-episode schizophrenia.

Authors:  R S Kahn; I E Sommer
Journal:  Mol Psychiatry       Date:  2014-07-22       Impact factor: 15.992

Review 10.  Presynaptic dopaminergic function: implications for understanding treatment response in psychosis.

Authors:  I Bonoldi; O D Howes
Journal:  CNS Drugs       Date:  2014-07       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.